

joints, newly referred to the outpatient Early Arthritis Clinic (EAC) in Amsterdam from 1995 to 1998. The median duration of complaints was 3 months, with a maximum duration of 3 years. Excluded from this EAC group were patients with other rheumatic diseases such as spondyloarthritis, crystal induced arthropathy, systemic lupus erythematosus, Sjögren's syndrome, and osteoarthritis¹⁰. The diagnosis of RA was made according to the clinical assessment of an experienced rheumatologist in 258 patients (70% female, median age 57 yrs, range 18–86). The remaining 121 non-RA patients were denoted uPA (65% female, median age 53 yrs, range 17–84); 73 of the patients with uPA had polyarthritis and 48 had oligoarthritis.

At the first visit, IgG anti-CCP antibodies were measured using the Immunoscan RA ELISA kit (Euro-Diagnostika, Arnhem, The Netherlands). IgM-RF and IgA-RF were measured on an ES300 immunochemistry analyser (Roche Diagnostics). Seven hundred microliters of biotinylated rabbit IgG (20 µg/ml phosphate buffered saline, PBS) were pipetted into streptavidin coated tubes together with 20 µl serum diluted 1:50 in PBS containing 0.05% Tween-20 and 2% bovine serum albumin. The tubes were developed with 500 µl diluted F(ab)₂ anti-human IgM or IgA, conjugated to horseradish peroxidase (Dako Diagnostics). For IgM-RF the standards were calibrated against the RELARES reference serum containing 200 IU/ml.

RESULTS

Optimal cutoff values to differentiate RA patients from uPA patients were deduced from receiver operating characteristics (ROC) curves. These were 30 IU/ml for IgM-RF, 10 arbitrary units (AU)/ml for IgA-RF, and 50 AU/ml for anti-CCP with specificities of 93.4%, 94.2%, and 97.5%, respectively, and sensitivities of 50.4%, 52.7%, and 42.6% (Table 1).

The next task was to find a combination of tests with the highest possible sensitivity and specificity for detecting RA. Because the specificity of anti-CCP was higher than that of IgM-RF, we first tried to enhance the specificity of the RF determination. This was done in 2 ways. When both IgM-RF > 30 and IgA-RF > 10 were combined into one cutoff criterion, the specificity increased to 96.7%, which is nearly as high as the specificity of anti-CCP (Table 1). However, exactly the same specificity and sensitivity were obtained by increasing the cutoff value for IgM-RF to 40 IU/ml (Table 1). Thus the IgA-RF determination to enhance the specificity of the RF determination has no additional value in this group of patients.

Table 1. Sensitivities and specificities of tests and combinations of tests for diagnosis of RA. Tests were done at baseline in a group of patients with early arthritis comprising 258 early RA patients and 121 undifferentiated polyarthritis (uPA) patients. They are given for several cutoff values denoted IgM-RF > 30 or > 40 IU/ml, IgA-RF > 10 AU/ml, and anti-CCP > 50 AU/ml, respectively.

Criterion	Sensitivity, %	Specificity, %
IgM-RF > 30	50.4	93.4
IgA-RF > 10	52.7	94.2
Anti-CCP > 50	42.6	97.5
IgM-RF > 40	46.5	96.7
IgM-RF > 30 and IgA-RF > 10	46.5	96.7
IgM-RF > 40 or anti-CCP > 50	55.4	96.7
IgM-RF > 40 and anti-CCP > 50	33.3	97.5

Both the IgM-RF > 40 and anti-CCP > 50 criteria had a high specificity, but the sensitivities were low. Therefore, the second step was to enhance the sensitivity by combining these 2 assays. It appeared that in one-quarter of the RA patients, IgM-RF and anti-CCP positivity were independent from each other: 24 RA patients (9%) were negative for the IgM-RF > 40 criterion, but positive for the anti-CCP > 50 criterion, whereas 33 RA patients (13%) were positive for the IgM-RF > 40 criterion but negative for anti-CCP > 50. In the group of uPA patients, none was negative for the IgM-RF > 40 criterion but positive for anti-CCP > 50, and one patient was positive for IgM-RF > 40 but negative for the anti-CCP > 50 criterion. This indicated that the 2 tests measured different entities and might be combined into a logical "or" criterion (either one test positive or the other or both positive). The best test criterion proved to be IgM-RF > 40 or anti-CCP > 50, with a sensitivity of 55.4% and specificity of 96.7% (Table 1). When this was compared with our routine assay for RF (the IgM-RF determination with a cutoff value of 30 IU/ml), the sensitivity increased from 50.4% to 55.4% and the specificity increased from 93.4% to 96.7%. When the combination criterion IgM-RF > 40 or anti-CCP > 50 was applied, 4 of the 121 uPA patients were positive, instead of 8 of the 121 uPA patients with the IgM-RF > 30 criterion.

One hundred fifteen patients were clinically diagnosed as RA without the presence of either IgM-RF > 40 or anti-CCP > 50 antibodies at baseline. In 84 of these patients, serum was available at 1 year followup. Only 2 patients became positive at 1 year, one with IgM-RF of 58 IU/ml and the other with anti-CCP of 101 AU/ml.

DISCUSSION

It is noteworthy that in a similar study⁷ a different conclusion was reached as to how IgM-RF and anti-CCP are to be combined into one discrimination criterion. The authors tried to discriminate RA from non-RA patients in the EAC of Leiden, The Netherlands. The sensitivity and specificity of their IgM-RF tests were 54% and 91%, respectively, and for anti-CCP measurements 48% and 96%. The main difference with the present study was the low specificity of their IgM-RF assay of 91%. When either IgM-RF positive or anti-CCP positive were combined into one criterion the sensitivity became high (63%) but the specificity decreased to 88%. Therefore they suggested combining IgM-RF and anti-CCP in such a way that both tests must be positive. In this case their specificity increased to 98% but their sensitivity decreased to 39%. When this criterion IgM-RF > 40 and anti-CCP > 50 was applied to our group of patients, only one-third remained positive (Table 1), too low for practical use.

We conclude that in our group of patients with early arthritis the criterion IgM-RF > 40 or anti-CCP > 50 is able to predict which patients with early arthritis will receive a

clinical diagnosis of RA with a sensitivity of 55.4% and a specificity of 96.7%.

Thus, anti-CCP testing combined with IgM-RF testing has additional value over IgM-RF testing alone in patients with early undifferentiated oligo and polyarthritis.

REFERENCES

1. Smolen JS. Autoantibodies in rheumatoid arthritis. In: Venrooij WJ, Maini RN, editors. *Manual of biological markers of disease*. Dordrecht: Kluwer Academic Publishers; 1996.
2. Jonsson T, Steinsson K, Jonsson H, Geirsson AJ, Thorsteinsson J, Valdimarsson H. Combined elevation of IgM and IgA rheumatoid factors has very high diagnostic specificity for rheumatoid arthritis. *Rheumatol Int* 1998;18:119-22.
3. Swedler W, Wallman J, Froelich CJ, Teodorescu M. Routine measurement of IgM, IgG and IgA rheumatoid factors: High sensitivity, specificity and predictive value for rheumatoid arthritis. *J Rheumatol* 1997;24:1037-44.
4. van Jaarsveld CHM, ter Borg EJ, Jacobs JWG, et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. *Clin Exp Rheumatol* 1999;17:689-97.
5. Schellekens GA, de Jong BAW, van den Hoogen FHI, van de Putte LBA. Citrulline is an essential constituent of antigenic determinants recognised by rheumatoid arthritis-specific autoantibodies. *J Clin Invest* 1998;101:273-81.
6. Kroot EJA, de Jong BAW, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. *Arthritis Rheum* 2000;43:1831-5.
7. Schellekens GA, Visser H, de Jong BAW, et al. The diagnostic properties of rheumatoid arthritis antibodies recognising cyclic citrullinated peptide. *Arthritis Rheum* 2000;43:155-63.
8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
9. van der Horst-Bruinsma IE, Speyer I, Visser H, Breedveld FC, Hazes JM. Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. *Br J Rheumatol* 1998;37:1084-8.
10. Jansen LMA, van Schaardenburg D, van der Horst-Bruinsma IE, Bezemer PD, Dijkmans BAC. Predictors of functional status in patients with early rheumatoid arthritis. *Ann Rheum Dis* 2000;59:223-6.